Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2022-10-01 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is a short notice dated October 1, 2022, addressed to stock exchanges (BSE and NSE) regarding the closure of the trading window for insiders and designated employees due to upcoming financial results for the quarter and half year ended September 30, 2022. It does not contain any financial data or results itself, nor does it provide detailed financial analysis or report. It is an announcement related to compliance with insider trading regulations and the timing of the trading window closure. The document length is only 1417 characters, indicating it is a brief announcement rather than a full report. Therefore, it does not qualify as an Interim/Quarterly Report (IR) or Earnings Release (ER). It is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance-related notices that do not fit other categories.
2022-10-01 English
Annual General Meeting
Regulatory Filings
2022-09-28 English
Annual General Meeting
AGM Information Classification · 100% confidence The document is titled as the "Outcome/Summary of Proceedings of the 29th Annual General Meeting (AGM)" of Medicamen Biotech Limited held on September 27, 2022. It details the agenda items discussed and transacted at the AGM, including adoption of audited financial statements, dividend declaration, director appointments, and auditor re-appointment. It also includes the proceedings of the meeting such as attendance, chairman's speech, voting process, and conclusion. The document does not contain the full financial statements or detailed financial analysis but rather a summary of the AGM proceedings and resolutions passed. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or summaries of the meeting proceedings. The document length (9211 characters) is sufficient to be more than a brief announcement but it is clearly a summary of the AGM, not the full Annual Report or financial statements themselves. Therefore, the correct classification is AGM Information (AGM-R).
2022-09-27 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting. It details the allotment of equity shares and fully convertible warrants by way of preferential allotment, including the names of allottees and the number of shares/warrants allotted. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an announcement of decisions made by the Board related to capital raising activities, not a full financial report or detailed financial statements. The document length is 3244 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes through preferential allotment of shares and warrants.
2022-09-12 English
Book Closure
Notice of Dividend Amount Classification · 90% confidence The document is an intimation regarding the book closure dates for the 29th Annual General Meeting (AGM) and the record date for dividend entitlement. It is addressed to stock exchanges and informs about administrative details related to the AGM and dividend payment. The document does not contain financial statements, detailed financial performance, or management discussion. It is a notification about the AGM schedule and dividend record date, which is typical of an announcement related to dividend or AGM logistics. Given the short length (1742 characters) and the nature of the content, it is not the AGM materials themselves but an announcement related to dividend and AGM dates. The closest fitting category is Notice of Dividend Amount (DIV) because it discusses the final dividend payment timing and record date, although the exact dividend amount is not stated, the document is primarily about dividend entitlement and payment timing. Therefore, the best classification is DIV with high confidence.
2022-09-08 English
Newspaper Advertisements
Regulatory Filings
2022-09-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.